Amount of Funding. In consideration of MTI's performance of its obligations under the Research Program, (a) Sankyo paid MTI a research fee of US$3,500,000 for each of the first two Research Years during the term of the Research Program, and (b) Sankyo shall pay a research fee of US$3,500,000 for the third Research Year during the term of the Research Program, of which US$1,750,000 remains outstanding.
Appears in 2 contracts
Samples: Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc), Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)
Amount of Funding. In consideration of MTI's performance of its obligations under the Research Program, (a) Sankyo paid MTI a research fee of US$3,500,000 for each of the first two four Research Years during the term of the Research Program, Program and (b) Sankyo shall pay a research fee of US$3,500,000 for the third fifth Research Year during the term of the Research Program, of which US$1,750,000 remains outstanding.
Appears in 2 contracts
Samples: Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc), Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)
Amount of Funding. In consideration of MTI's performance of its obligations under the Research Program, (a) Sankyo paid paid, or in the case of the third year will pay, MTI a research fee of US$3,500,000 ofUS$3,500,000 for each of the first two three Research Years during the term of the Research Program, and (b) Sankyo shall pay a research fee of US$3,500,000 ofUS$3,500,000 for the third fourth Research Year during the term of the Research Program, of which US$1,750,000 remains outstanding.
Appears in 2 contracts
Samples: Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc), Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)